PROGRAMMA - SIF

FRIDAY, October 16, 2009
FRIDAY, October 16, 2009
Poster Area
Poster Display: for the duration of the day (8.30 am-6.45 pm)
Author’s attendance at poster site: the author in bold will be available at the
poster site between 2.00 and 4.00 pm
Poster board
No.:
P-2/4/1
P-2/4/2
P-2/4/3
P-2/4/4
P-2/4/5
Poster Session
P-2/4: CHEMOTHERAPY
Poster Commission Members:
President: Viano I. (Novara)
Members: Bertazzoni Minelli E. (Verona),
D’Alessandro N. (Palermo)
THYMOL INHIBITS GARDNERELLA VAGINALIS ADHESION
TO HUMAN VAGINAL CELLS
Braga P., Dal Sasso M., Spallino A., Culici M., Sturla C.
(Milan, Gallarate)
NEW HPLC–MS METHOD FOR THE SIMULTANEOUS
QUANTIFICATION IN HUMAN PLASMA OF THE
ANTILEUKEMIA DRUGS IMATINIB, DASATINIB, AND
NILOTINIB
De Francia S., D’Avolio A., De Martino F., Pirro E.,
Piccione F., Racca S., Di Carlo F. (Orbassano, Turin)
MITOTANE: THE IMPORTANCE OF MONITORING IN
ADRENOCORTICAL CANCER PATIENTS
De Martino F., De Francia S., Pirro E., Piccione F., Terzolo
M., Daffara D., Di Carlo F. (Orbassano)
ANTI-ENDOTHELIAL EFFECTS OF LOW DOSE CERAMIDE
ANALOGS IN VITRO AND IN VIVO
Fioravanti A., Orlandi P., Di Desidero T., Canu B., Danesi
R., Del Tacca M., Bocci G. (Pisa)
IRINOTECAN AND AXITINIB SYNERGISTICALLY INHIBIT
PANCREATIC CANCER IN VITRO AND IN VIVO BY
MODULATING VEGFR-2, ABCG2 AND ATP7A GENE
EXPRESSION AND TSP-1 SECRETION
Canu B., Fioravanti A., Di Desidero T., Orlandi P., Danesi
R., Del Tacca M., Bocci G. (Pisa)
P-2/4/6 THE IGF1R INHIBITOR NVP-AEW541 DISRUPTS A PRO-
110
P-2/4/7
P-2/4/8
P-2/4/9
P-2/4/10
P-2/4/11
P-2/4/12
P-2/4/13
P-2/4/14
SURVIVAL AND PRO-ANGIOGENIC IGF-STAT3-HIF1
PATHWAY IN HUMAN GLIOBLASTOMA CELLS
Ravizza R., Molteni R., Monti E., Gariboldi M. (Busto
Arsizio)
MODULATION OF MMP-9 IN U87MG GLIOBLASTOMA CELLS
BY A3 ADENOSINE RECEPTORS
Gessi S., Sacchetto V., Fogli E., Merighi S., Varani K.,
Baraldi P., Tabrizi M., Leung E., Mac Lennan S., Borea P.
A. (Ferrara, Cary)
THERMODYNAMICS OF A2B ADENOSINE RECEPTOR
BINDING DISCRIMINATES AGONISTIC FROM
ANTAGONISTIC BEHAVIOUR
Sacchetto V., Gessi S., Fogli E., Varani K., Merighi S.,
Leung E., MacLennan S., Borea P. A. (Ferrara, Cary)
GEMCITABINE-LOADED PEGYLATED UNILAMELLAR
LIPOSOMES VS GEMZAR ® : BIODISTRIBUTION,
PHARMACOKINETIC FEATURES AND IN VIVO ANTITUMOR
ACTIVITY
D’Agostino M., Paolino D., Cosco D., Celano M.,
Racanicchi L., Trapasso E., Celia C., Iannone M., Puxeddu
E., Costante G., Russo D., Fresta M. (Catanzaro, Milan,
Messina, Roccelletta di Borgia, Perugia)
CORRELATION BETWEEN IN VITRO AND IN VIVO
CYTIDINE DEAMINASE PHENOTYPE AND GEMCITABINE
PHARMACOKINETICS IN PATIENTS WITH SOLID TUMORS
Gusella M., Modena J., Barile C., Toso S., Bononi A.,
Menon D., Pasini F., Padrini R. (Rovigo, Padua)
PRELIMINARY IN VITRO BIOLOGICAL EVALUATIONS OF
NEW PRODRUGS DESIGNED AS ANTIMELANOMA AGENTS
Nassi A., Ruzza P., Rosato A., Rondina M., Rossi C.,
Floreani M., Quintieri L. (Padua)
CURCUMIN INCREASES SENSITIVITY OF RESISTANT
OVARIAN TUMOUR CELLS TO PLATINUM DRUGS:
APOPTOTIC EFFECTS AND CELL-CYCLE ALTERATIONS
Montopoli M., Ragazzi E., Froldi G., Dorigo P., Caparrotta
L. (Padua)
AN EVALUATION OF ANTIBIOTIC USE AND RESISTANCE IN
AN ITALIAN UNIVERSITY HOSPITAL
Silvani M., Poluzzi E., Motola D., Biagi C., Nanetti A.,
Ambretti S., Fiacchi P., Puggioli C., Vaccheri A., Montanaro
N. (Bologna)
IN VITRO INVESTIGATION OF SULINDAC DERIVATIVES AS
POTENTIAL ANTICANCER AGENTS
111
FRIDAY, October 16, 2009